For other countries, any question or an interest in distributing OncoDEEP in your country please contact us at firstname.lastname@example.org
OncoSELECT is a fast, minimally invasive analysis of circulating tumour DNA from a blood sample for lung (NSCLC), colon, breast (ER+ or HER2+) and prostate cancer patients. OncoSELECT is the perfect diagnostic tool to:
OncoSELECT is unique because it is focusing only on the targets that matters specifically for each cancer type, while directing the analysis on the essentials markers for treatment response or resistance.
Currently OncoDNA is offering 4 versions of OncoSELECT for:
According to a recent change in FDA guidelines, liquid biopsy is now approved as the first diagnostic tool for Non-Small Cell Lung Cancer patients. OncoSELECT is the perfect test to make a first screening of the most relevant genes related to treatments. For monitoring purposes, OncoSELECT should ideally be performed in the middle of the treatment and 2 weeks after the last dose has been given. Subsequently, it will depend on the treatment, the cancer type and the anamnesis of the patient. Our suggestion is to perform the follow-up every three month or at the frequency decided by the oncologist.
OncoDNA provides multiples solutions for the right cancer approach and cancer treatment
The unique personalized non-invasive blood based solution to monitor the evolution of the tumor and the effectiveness of the treatment.Learn more
OncoDNA, with over 60 years’ expertise in medical diagnostics, was founded by a team of experts with many years of experience in DNA sequencing and diagnostic analyses in oncology.